1. Public information inquiry shows that Boya Bio paid 8180,000 yuan to buy plasma, which was never delivered, concealing the actual operation of the company and obtaining illegal benefits.
2. The controlling shareholder, Gao Tejia Investment Group, and the directors of the company have reduced their holdings and cashed in, and the executives have been leaving.
3. Gao Tejia holds more than 30% of the company's shares, but Boya Bio has no actual controller, which leads to information asymmetry and increased investment risk.
Therefore, we must pay attention to the company's financial situation, internal management and information disclosure to avoid investment risks.